Manuel Carcelen, MD
Pulmonary Disease · Birmingham, ALNPI 1538124607
Payments from drug & device makers
Across 311 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$535
- Grifols USA, LLC$474
- Boehringer Ingelheim$288
- Electromed, Inc.$147
- plus $1K from 17 others
What the payments were for
- Food & beverage$5,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,539 |
| GSK | 107 | $1,404 |
| Regeneron Healthcare Solutions, Inc. | 20 | $535 |
| Grifols USA, LLC | 23 | $474 |
| Boehringer Ingelheim | 18 | $288 |
| Electromed, Inc. | 16 | $147 |
| Baxter Healthcare | 4 | $135 |
| Genentech USA, Inc. | 6 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Mylan Specialty L.p. | 6 | $115 |
| Sanofi | 4 | $103 |
| Jazz Pharmaceuticals Inc. | 5 | $101 |
| Harmony Biosciences LLC | 3 | $75 |
| Philips North America LLC | 3 | $70 |
| Mallinckrodt Hospital Products Inc. | 2 | $68 |
| Novartis | 3 | $63 |
| Mallinckrodt Enterprises LLC | 2 | $60 |
| Amgen | 2 | $43 |
| Pfizer | 2 | $41 |
| Shire North American Group Inc | 1 | $20 |
| Boston Scientific | 1 | $16 |
| Pulmonx Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,575 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 322 | $239,869 |
| OfevNintedanib Esylate | 17 | $220,761 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $124,293 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 217 | $109,204 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $92,352 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $60,364 |
| Spiriva RespimatTiotropium Bromide | 49 | $30,380 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 44 | $28,784 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $20,743 |
| Incruse ElliptaUmeclidinium Bromide | 59 | $20,662 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $12,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 458 | $11,058 |
| DuleraMometasone/Formoterol | 31 | $10,892 |
| Spiriva HandihalerTiotropium Bromide | 17 | $10,850 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $10,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,404 | $438,458762 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $288 | $289,265130 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $123 | $124,29312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,539 | $120,116245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$1.7M
- Bryan GarciaBirmingham$606K
- Veena AntonyBirmingham$327K
- Steven RoweBirmingham$252K
- Derek RussellBirmingham$190K
- Raymond WadeBirmingham$135K
- Joseph Thachuthara-GeorgeBirmingham$126K
- Jennifer TrevorBirmingham$99K
- Peter MorrisBirmingham$94K
- Amanda DenhamBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.